International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016
Topics
Meeting category
Date(s)
8 Jun 2016 - 10 Jun 2016
Location
Washington DC, United States
Organizer
Platinum Level Support
Sponsor logos
ViiW

International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016

Related Enduring Materials

Slidesets
35
Videos
11
Enduring Materials
-
Other Viruses: using Wolbachia to interrupt transmission of viral infections such as Dengue, Chikungunya and Zika
Steven Kern
Steven Kern, PhD
Bill & Melinda Gates Foundation, USA
Slideset
Video
Pharmacokinetics in infants and young children -
Pharmacokinetic, Safety and Efficacy of Darunavir/Ritonavir in HIV+ Pregnant Women
placeholder3
Dr. Minh Patrick Le
Hôpital Bichat-Claude Bernard, France
Slideset
Raltegravir (RAL) Pharmacokinetics (PK) and Safety in HIV-1 Exposed Neonates at High Risk of Infection (IMPAACT P1110)
placeholder3
Dr. Diana Clarke
Boston Medical Center, USA
Slideset
Timing of the postpartum curve in pharmacokinetic studies in pregnancy should not be too early
Angela Colbers
Angela Colbers, PhD
Radboudumc, the Netherlands
Slideset
Hepatitis resistance and pharmacokinetics of DAAs -
Role of Resistance Testing
Shyam Kottilil
Shyam Kottilil, MD, PHD
University of Maryland, USA
The FDA Perspective on Hepatitis C Drug Resistance
Patrick Harrington
Patrick Harrington, PHD
FDA, USA
Slideset
Video
Effect of Renal Impairment on Drugs Primarily Eliminated by Metabolism or Biliary Excretion: Review of Data from HCV DAA Drugs and Literature
placeholder3
Dr. Tushar Garimella
Bristol-Myers Squibb, USA
Slideset
Effect of daclatasvir/asunaprevir/beclabuvir in fixed-dose combination on the pharmacokinetics of CYP450/transporter substrates in healthy subjects
placeholder3
Dr. Tushar Garimella
Bristol-Myers Squibb, USA
Slideset
Evaluation of Drug-Drug Interaction Between Sofosbuvir/Velpatasvir and Rifaximin in HCV-Infected Subjects with Moderate Hepatic Impairment
placeholder3
Erik Mogalian
Gilead Sciences, USA
Slideset
Compartmental penetration of Antiretrovirals -
Cumulative tenofovir exposure is associated with decreased BMD in young and old HIV-infected adults on tenofovir based regimens
placeholder3
Sharon Seifert, PhramD
University of Colorado Denver, USA
Slideset
Intracellular Metabolism of Tenofovir Alafenamide in Cervical and Vaginal Epithelial Cells
Mackenzie Cottrell
Mackenzie Cottrell, PharmD
University of North Carolina, USA
Slideset
Pharmacogenetics of Efavirenz Discontinuation for Central Nervous System Symptoms at a Southeastern United States Clinic May Differ by Race
placeholder3
Paul Leger, MD, MPH
Vanderbilt University Medical Center, USA
Slideset
Virologic and Immunologic Responses to Raltegravir and Dolutegravir in GALT of HIV+ Men and Women
placeholder3
Michael Weber, PharmD
University of North Carolina at Chapel Hill, USA
Slideset
Long Acting Antivirals -
Target Concentrations
Angela Kashuba
Angela DM Kashuba, BScPhm, PharmD, DABCP, FCP
University of North Carolina, Chapel Hill, United States
Slideset
Video
FDA Perspective on "oral run-in" phase
Yodit Belew
Dr. Yodit Belew
FDA, USA
Slideset
ViiV - Cabotegravir
Bill Spreen
Bill Spreen, PharmD
ViiV, USA
Slideset
Janssen - Rilpivirine
Herta Crauwels
Herta Crauwels, PhD
Janssen, Belgium
Slideset
Video
Efficacy of once-weekly MK-8591 in SIV infected rhesus macaques
placeholder3
Dr. Matthew Rizk
Merck, USA
Slideset
In silico pharmacokinetic/pharmacodynamic simulation of long acting tenofovir injectable formulation for pre exposure prophylaxis strategies.
placeholder3
Dr. Paul Curley
University of Liverpool, United Kingdom
Slideset
Back to the Future: 40 years of Clinical Pharmacology -
Looking Backwards: Hormonal Contraception and ART
Kimberly Scarsi
Kimberly Scarsi, PharmD, MS, FCCP
University of Nebraska Medical Center (UNMC), United States
Slideset
Video
Pharmacogenetics - Back to reality
Owen, Andrew
Andrew Owen, BSS, MSC, PhD, FSB
University of Liverpool, United Kingdom
Slideset
Video
Will we see the Back of DDIs?
Catia Marzolini
Catia Marzolini, PharmD, PhD
University Hospital Basel, Switzerland
Slideset
Video
The ‘Back Side’ of Compartments
Saye Khoo
Saye Khoo, MD, PhD
Royal Liverpool University Hospital; University of Liverpool, United Kingdom
Slideset
Video
Back-terial co-infections
Mohammed Lamorde
Mohammed Lamorde, FRCP, PhD
Infectious Diseases Institute, Makerere University College Of Health Sciences, Uganda, Africa
Slideset
Video
Backing up clinical data with modelling
Marco Siccardi
Marco Siccardi, PhD
University of Liverpool, United Kingdom
Slideset
Video
Clinical Guidance on how to interpret DDI’s -
Specific Complex Interactions (mechanic presentation)
David Burger
David Burger, PharmD, PhD
Radboud UMC, The Netherlands
Slideset
Video
PK/PD of new and existing antivirals -
PBPK/PD Modeling and Simulations to Guide Dose Recommendation of Amlodipine after Co-administration with Viekirax or Viekira Pak
Dwaipayan Mukherjee, PhD
AbbVie, USA
Slideset
Effects of Sofosbuvir/Ribavirin Treatment and ITPA Phenotype on Endogenous Purines
Dr. Leah Jimmerson
University of Colorado, USA
Slideset
Rifampin (RIF) Decreases Cabotegravir (CAB) Exposure following Oral Coadministration
Dr. Susan Ford
GlaxoSmithKline, USA
Slideset
Increased Tenofovir Diphosphate in Red Blood Cells, but Not Tenofovir in Plasma, with Sofosbuvir and Ribavirin
Dr. Christine MacBrayne
University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, USA
Slideset
MK-3682, a HCV NS5B Inhibitor with a Broad Spectrum of HCV Genotypic Activity, Demonstrates Potent Antiviral Activity in Genotypes -1,-2, and -3 HCV-Infected Patients
Dr. Nancy Kim
Merck & Co., USA
Slideset
Clinical Pharmacology Updates on New Compounds -
Pharmacokinetics of Darunavir, Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir and Ribavirin in Adults Infected with Hepatitis C Virus (HCV) Genotype (GT) 1 and Human Immunodeficiency Virus Type 1 (HIV-1)
Dr. Jennifer King
Abbvie, USA
Slideset
Physiologically-based simulation of daclatasvir pharmacokinetics with antiretroviral inducers and inhibitors of cytochrome P450 and drug transporters
Dr. Timothy Eley
Bristol-Myers Squibb, USA
Slideset
A Clinically Meaningful Drug-Drug Interaction Observed Between ZepatierTM (Grazoprevir/Elbasvir) and Stribild® HIV Fixed-Dose Combination in Healthy Subjects
Dr. Hwa-Ping Feng
Merck Sharpe & Dohme Corp., a subsidiary of Merck and Co., Inc., USA
Slideset
Pharmacokinetics of Dolutegravir after Switching to Abacavir/Dolutegravir/Lamivudine from an Efavirenz Based Regimen: A PK Substudy from Striiving
Dr. Jeff de Wet
ViiV Healthcare, USA
Slideset
Evaluation of Pan Genotypic HCV NS3/4A Protease Inhibitor GS-9857 as the Object of Transporter and Cytochrome P450-Mediated Drug-Drug Interactions
Dr. Brian Kirby
Gilead Sciences, USA
Slideset
Overview

Dear Colleague, 

The 17th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy, held from 8 - 10 June 2016 in Washington DC, USA was an enormous success.

The Organizing Committee would like to thank all invited speakers and participants for their contribution to this workshop!

In particular we would like to thank our sponsors ViiV Healthcare, BMS, Gilead, and Janssen for making this workshop possible.

The Organizing Committee

Support
Platinum Level
Silver Level
Support
Language
Afbeelding
Magdalena Pawlowska
Caption
Hi! I'm Magdalena
Label / Name
How can I help you?
Go to Contact form webform